3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Carcinoma, Hepatocellular
8
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Liver Malignancy
1
Hepatic Malignancies
1
Carcinoma, Ovarian Epithelial
1
Bile Duct Neoplasms
1
Interventions
lutetium Lu 177 dotatate
29
Everolimus
19
Temozolomide
11
gallium Ga 68 dotatate
10
Nivolumab
10
Magnetic Resonance Spectroscopy
10
Capecitabine
9
pembrolizumab
8
lanreotide
8
Positron Emission Tomography Computed Tomography
8
cabozantinib
7
3-Iodobenzylguanidine
7
177Lu-octreotide, DOTA(0)-Tyr(3)-
7
Somatostatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
lenvatinib
5
Octreotide
5
Lutetium-177
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Carboplatin
5
avelumab
4
Positron-Emission Tomography
4
Ipilimumab
4
Bevacizumab
4
surufatinib
3
pasireotide
3
fluorodopa F 18
3
copper dotatate CU-64
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Neuroendocrine Tumors
×
Yttrium-90
×
Clear all
NCT04339036
2026-06-04
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
70 enrolled
NCT04790708
2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA
Unknown
250 enrolled